Department of Cardiology, West Virginia University, Morgantown, WV, United States of America.
Department of Cardiology, Mayo Clinic School of Medicine, Rochester, MN, United States of America.
Cardiovasc Revasc Med. 2022 Jan;34:121-125. doi: 10.1016/j.carrev.2021.01.021. Epub 2021 Jan 22.
Data on the differential impact of chronic kidney disease (CKD) on the outcomes of endovascular stroke interventions (ESI) for acute ischemic stroke (AIS) are limited.
Adult patients who underwent ESI for AIS between October 1st, 2015 and September 30th, 2019, were identified in a national multicenter database. The primary endpoints were in-hospital mortality and poor functional outcomes. Secondary endpoints included intracranial hemorrhage, mechanical ventilation, pneumonia, myocardial infarction, blood transfusion, length of stay, and cost. A multilevel mixed-effects regression model was used to derive adjusted outcomes.
A total of 22,193 AIS patients who underwent ESI at 99 centers were included. Among those, 18,881 (85%) had no CKD, and 3312 (15%) had CKD. Patients with CKD were older and had a higher prevalence of key comorbidities. After multivariable risk adjustment, patients with CKD had significantly higher in-hospital mortality (Odds Ratio [OR] 1.55 [95% Confidence Interval] [CI] 1.40-1.73, p < 0.01), and poor functional outcomes (OR 1.38, 95%CI 1.26-1.50, p < 0.01). Major complications, including mechanical ventilation, pneumonia, blood transfusion, and myocardial infarction, were more common among CKD patients, who also had longer hospitalizations and accrued higher cost.
The presence of CKD in patients with AIS treated with ESI is an independent predictor of in-hospital mortality and poor functional outcomes at discharge.
关于慢性肾脏病(CKD)对急性缺血性脑卒中(AIS)血管内治疗(ESI)结局影响的差异的数据有限。
在一个全国多中心数据库中,确定了 2015 年 10 月 1 日至 2019 年 9 月 30 日期间接受 ESI 治疗的 AIS 成年患者。主要终点为住院期间死亡率和不良功能结局。次要终点包括颅内出血、机械通气、肺炎、心肌梗死、输血、住院时间和费用。使用多水平混合效应回归模型得出调整后的结果。
共纳入 22193 例在 99 个中心接受 ESI 的 AIS 患者。其中,18881 例(85%)无 CKD,3312 例(15%)有 CKD。CKD 患者年龄较大,且合并症更为常见。经过多变量风险调整后,CKD 患者的住院期间死亡率显著升高(优势比 [OR] 1.55 [95%置信区间] [CI] 1.40-1.73,p<0.01),且不良功能结局的发生率更高(OR 1.38,95%CI 1.26-1.50,p<0.01)。CKD 患者更易发生机械通气、肺炎、输血和心肌梗死等主要并发症,住院时间更长,费用更高。
在接受 ESI 治疗的 AIS 患者中,CKD 的存在是住院期间死亡率和出院时不良功能结局的独立预测因素。